A Randomized, Open-label, Comparative Study to Estimate the Effect of Darbepoetin Alfa on Hospital Days, Economic Outcomes, and Health-related Quality of Life in Subjects With Nonmyeloid Malignancies and Anemia of Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care
to estimate the difference in number of hospital days, number of subject hospitalized, and number of hospitalizations over 12 weeks between subjects by randomized treatment group
12 weeks
No
MD
Study Director
Amgen
United States: Food and Drug Administration
20000219
NCT00989092
May 2002
June 2004
Name | Location |
---|